Publication Name	World Journal of Gastroenterology
Manuscript ID	8864
Country	China

Received	2014-01-09 11:40
Peer-Review Started	2014-01-09 21:39
To Make the First Decision	2014-01-24 14:57
Return for Revision	2014-01-26 16:12
Revised	2014-03-06 17:35
Second Decision	2014-06-05 10:36
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-06-05 11:11
Articles in Press	2014-06-05 11:21
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-06-16 06:48
Typeset the Manuscript	2014-10-10 13:49
Publish the Manuscript Online	2014-10-20 18:35

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, Research & Experimental
Manuscript Type	Autobiography
Article Title	FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation
Manuscript Source	Unsolicited Manuscript
All Author List	Jun Yao, Chun-Suo Zhou, Xiong Ma, Bai-Qing Fu, Li-Sheng Tao, Miao Chen and Ya-Ping Xu
Funding Agency and Grant Number
Corresponding Author	Ya-Ping Xu, Chief Physician, Department of Gastroenterology, the People’s Hospital Affiliated to Jiangsu University, 8 Dianli Road, Zhenjiang 212002, Jiangsu Province, China. yapingxu@yeah.net
Key Words	Farnesoid X receptor; Nonalcoholic fatty liver disease; GW4064; Nonalcoholic fatty liver disease activity score; Lipopolysaccharide-induced hepatic inflammation; Macrophage activation
Core Tip	We found that the synthetic farnesoid X receptor (FXR) agonist GW4064 attenuated lipopolysaccharide-induced hepatic injury in high-fat diet-fed mice by reducing proinflammatory cytokine expression in macrophages. Moreover, we found that FXR expression was decreased in patients with nonalcoholic steatohepatitis, the most extreme form of nonalcoholic fatty liver disease (NAFLD), and was inversely correlated with the NAFLD activity score. Together, these findings provide insights into the etiology of NAFLD and suggest that FXR activation with synthetic agonists may represent a potential therapeutic option for patients with NAFLD, which we believe will be of great interest to the readers of the journal.
Publish Date	2014-10-20 18:35
Citation	Yao J, Zhou CS, Ma X, Fu BQ, Tao LS, Chen M, Xu YP. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation. World J Gastroenterol 2014; 20(39): 14430-14441
URL	http://www.wjgnet.com/1007-9327/full/v20/i39/14430.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i39.14430

Full Article (PDF)	WJG-20-14430.pdf
Full Article (Word)	WJG-20-14430.doc
Manuscript File	8864-Review.doc
Answering Reviewers	8864-Answering reviewers.pdf
Copyright License Agreement	8864-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	Editing_Certificate_20140109103254.pdf
Peer-review Report	8864-Peer reviews.pdf
Scientific Misconduct Check	8864-CrossCheck.jpg
Scientific Editor Work List	8864-Scientific editor work list.pdf